
Medtech company Ambu has downgraded its financial guidance for its accounting year of 2020/21 after sales and income for its Core business were affected by the challenging global shipping conditions.
Ambu announced in a stock exchange notification that it now expects total organic growth for the year of 16 percent, compared to a previous estimate of 17 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app